The US FDA is preparing to give the healthcare industry something it has been waiting for: clearer rules for generative AI in medical devices.
According to reporting by STAT, the agency is developing a regulatory framework for devices that use generative AI — the technology behind tools that can produce text, images or recommendations. The plan is to offer both broad guidance on generative AI overall and more narrowly tailored “specialty” guidance for particular applications that are especially complex or high-interest.
What officials are saying
“The ecosystem is expecting clarity. We seek to provide that clarity,” said Rick Abramson, director of the FDA’s Digital Health Center of Excellence. He added that the industry can expect “not only broad guidance on the overall topic of generative AI, but also some more narrowly constructed specialty guidance on particular…topics of special interest or special complexity.” The article did not attach a specific timeline.
Why it matters
Generative AI is spreading quickly into healthcare — from drafting clinical notes to supporting diagnosis — but developers have faced uncertainty about how the FDA will evaluate tools whose outputs can change and aren’t always predictable. Clear guidance could shape how quickly, and how safely, these tools reach patients. For now, this is a statement of regulatory intent, not a finalized rule.